30th Annual Luau and Legends of Surfing Invitational
|
Join Moores on August 26 and 27, 2023 for a fundraiser like no other. Over its 30 year history, the Annual Luau has raised over $10 million to support novel cancer research and improve patient care. This year, an in-person sponsor party will take place on Saturday evening, which will be followed by the Luau and Legends Invitational on Sunday morning. Tickets and volunteer opportunities still are available. Visit Website»
|
UC San Diego Rises to No. 4 Among U.S. Public Universities in Academic Ranking of World Universities (ARWU)
|
The 2023 ARWU has recognized UC San Diego as No. 4 among public universities in the United States, rising one spot from last year. UC San Diego also jumped two spots to No. 19 in the world. Read More»
|
2023 Moores Cancer Control Program Annual Retreat
|
Cancer Control Program Leaders Samir Gupta, MD, MSCS, AGAF and Noe Crespo, PhD, MPH cordially invite you to the 2023 Cancer Control Annual Retreat, to be held Wednesday, September 13, 2023. This year's retreat will feature keynote speaker Dr. Katrina Goddard and expert discussion on health equity, cancer screening, environmental, occupational, and climate change, cancer survivorship, and cancer control. Visit Website»
|
Building a Respectful, Inclusive Culture (BRIC) Program Extended to August 31, 2023
|
BRIC is a certificate program that helps UC San Diego, Health Sciences faculty fulfill it mission to build a teaching and training environment that is free of harassment and discrimination, to allow its trainees to thrive. Currently, the NIH recommends completing BRIC but may require completion in the future. BRIC is required by the NSF. Visit Website»
|
Clinical Trials Office (CTO) Transformation Initiative
|
The CTO Transformation Initiative is generating substantial excitement and progress among Moores faculty and staff. This initiative is paving the way for Moores to build a world-class CTO that supports its investigators, staff, and patients involved in clinical trials.
The initiative has made meaningful progress since its launch earlier this summer:
|
-
The Fast Lane initiative was launched to expedite clinical trial activation and clear the study backlog. Fast Lane aligns with a success statement, features long-term research strategy, and introduces an updated organizational structure that has been designed to enhance support and services for clinical trials.
-
To keep stakeholders well-informed throughout the initiative, CTO is hosting a series of Town Hall meetings. The first Town Hall was held on August 16 with MCC faculty to review details about Fast Lane and address faculty questions.
- In the coming weeks, Town Halls will be held with CTO staff to provide an overview of the new organizational structure and the opportunities that it will engender.
|
Many thanks to all who have participated in the CTO Transformation Initiative thus far, helping CTO navigate key transformation focus areas to drive high-priority improvements. Please watch this newsletter for updates on the initiative. Should you have any questions regarding the initiative, please attend upcoming Town Halls that will allocate time to answer your questions.
As you hear about upcoming changes or have questions regarding your specific role, you are welcome to reach out to CTO Leadership and/or HR with any questions.
|
|
|
August 26, 2023 | 8:30 a.m. PT
Bahia Resort Hotel, Mission Bay
|
August 30, 2023 | 1:00 p.m. PT
Goldberg Auditorium
|
September 13, 2023 | 11:30 a.m. PT
Goldberg Auditorium
|
August 31, September 6, and September 8, 2023 | 11:00 a.m. ET
Register by August 24, 2023
|
|
|
Early Career Cancer Research Information Session with Dr. Katrina Goddard
|
Early career trainees, such as junior faculty, post-doctoral fellows, pre-doctoral candidates, and students, are invited to join a small audience as Dr. Goddard (Director, NCI Division of Cancer Control and Population Sciences) talks with pre-selected Moores early-career cancer researchers about NCI opportunities to support their research and/or interests on Wednesday, September 13, 2023. This is a unique experience for trainees to listen to the conversation and gain insight of the opportunities, interests, foci, and future directions of the NCI.
Seats are limited, and RSVP is required for catering purposes—light breakfast will be provided. After clicking the RSVP button below, please use the "Respond" button on the following page to RSVP.
|
|
|
FEATURED FUNDING OPPORTUNITIES |
The BCRP Clinical Research Extension Award aims to (1) extend or expand the data collection, follow-up, and analysis of breast cancer clinical studies and (2) increase the clinically relevant effect of breast cancer patient participation in clinical research by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. Patient contributions of tissue, serum, and other biologic specimens and their data are invaluable to saving lives. This BCRP mechanism ensures that science values those contributions with research that maximizes their effect.
Deadline: Tuesday, September 12, 2023
|
This Notice of Funding Opportunity (NOFO) invites proposals for research centers to advance cancer control equity by stimulating community-engaged, multilevel research interventions that address the impact of social determinants of health (SDOH) on adverse cancer control outcomes. Each Research Center will (1) develop interventions that target the multilevel pathways by which SDOH impact adverse cancer outcomes, (2) develop measures, methods, and assess community-level SDOH, community engagement, and cancer control equity processes and outcomes, and (3) build capacity and engagement among scholars from diverse backgrounds, those from groups underrepresented in the biomedical sciences, and community partners to implement interventions that incorporate the lived experiences of those who face cancer inequities.
Deadline: Thursday, September 14, 2023
|
Proposed research projects may address any topic related to the scientific study of prostate cancer, which include—but are not limited to—the prevention, diagnosis, treatment, or etiology of prostate cancer. The proposed research may be basic, translational, behavioral, or clinical in nature. At this time, proposals are open to only faculty researchers.
Deadline: Friday, September 15, 2023
|
Proposed research projects may address any topic related to the scientific study of prostate cancer, which include—but are not limited to—the prevention, diagnosis, treatment, or etiology of prostate cancer. The proposed research may be basic, translational, behavioral, or clinical in nature. At this time, proposals are open to only faculty researchers.
Deadline: Tuesday, October 3, 2023
|
|
|
JAMA Otolaryngol Head & Neck Surgery
Joseph Califano (Structural and Functional Genomics) and Adam Burgoyne (Cancer Biology and Signaling)
| Molecular Pharmaceutics
Nicole F. Steinmetz (Solid Tumor Therapeutics)
|
Gut
Samir Gupta (Cancer Control Program)
|
|
|
GS-US-592-6238: A Randomized, Open-label, Phase III Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Patients with Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PDL1 or in Patients Previously Treated with Anti-PD(L)1 Agents in the Early Setting Whose Tumors Do Express PDL1
|
PI: Rebecca Shatsky
NCT: NCT05382286
|
GS-US-592-6173 (Ascent04): A Randomized, Open-label, Phase III Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice and Pembrolizumab in Patients with Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PDL1
|
PI: Rebecca Shatsky
NCT: NCT05382286
|
DSP107 001: A First-in-Human, Two-Part, Open-Label, Phase I/II Study of DSP107 in Subjects with Advanced Solid Tumors Including a Dose-escalation Safety Study (Part 1) and Preliminary Efficacy Assessment of DSP107 as Monotherapy and in Combination with Atezolizumab (Part 2)
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT (COE) |
Prostate Cancer in the Black and African American Community: Barriers and Solutions
Tuesday, August 29 | 12:00 p.m. to 1:00 p.m.
|
African American men exhibit an increased risk for developing prostate cancer, compared to white men and other men of color. Not only will one in six Black men will develop prostate cancer in his lifetime, but Black men also are 1.7 times more likely to be diagnosed with—and 2.1 times more likely to die from—prostate cancer than white men. Moreover, Black men are more likely than white men to be diagnosed with advanced disease. Against this backdrop, please join ZERO Prostate Cancer and COE virtually on August 29, 2023 to discuss barriers and solutions to prevent, find, treat, and survive prostate cancer in the Black and African American community. Members of the community, advocates, and practitioners all are welcome.
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to .
To continue receiving our emails, add us to your address book.
|
|
|
|
